Scholarlink

Background <p>TMPRSS2:ERG gene fusion is a common alteration in prostate cancer and is regulated by androgen receptor signaling. We investigated whether ERG expression, assessed by immunohistochemistry (IHC), predicts clinical outcomes in patients with intermediate- or high-risk localized prostate cancer treated with combined androgen blockade (CAB) and radiotherapy (RT).</p> Material and methods <p>We retrospectively analyzed patients treated with CAB (GnRH agonists + antiandrogens) and normofractionated RT. ERG expression was evaluated using IHC. Overall survival (OS) was estimated with Kaplan–Meier curves. Prostate cancer-specific survival (PCSS), biochemical recurrence-free survival (bRFS), and progression-free survival (PFS) were assessed using competing risk models.</p> Results <p>A total of 86 patients were included (median follow-up 173&#xa0;months). ERG expression was positive in 69%. No significant differences were observed in OS (HR 1.03; <i>p</i> = 0.92), PCSS (HR 0.44; <i>p</i> = 0.22), bRFS (HR 0.51; <i>p</i> = 0.19), or PFS (HR 0.56; <i>p</i> = 0.30) between ERG-positive and ERG-negative groups.</p> Conclusions <p>ERG expression assessed by IHC was not associated with clinical outcomes in this population. These results do not support its role as a predictive biomarker in patients treated with CAB and RT. Further prospective studies are warranted to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy

  • 期刊论文

  • 发表日期：

    2025年8月11日

查看全文
  • Ivan Henriquez,
  • Barbara Malave,
  • Gemma Benitez-Gabella,
  • David Parada,
  • Marta Canela,
  • Raquel García-Pablo,
  • Rocio Benavides,
  • Francesc Rius,
  • Meritxell Arenas

摘要

Background

TMPRSS2:ERG gene fusion is a common alteration in prostate cancer and is regulated by androgen receptor signaling. We investigated whether ERG expression, assessed by immunohistochemistry (IHC), predicts clinical outcomes in patients with intermediate- or high-risk localized prostate cancer treated with combined androgen blockade (CAB) and radiotherapy (RT).

Material and methods

We retrospectively analyzed patients treated with CAB (GnRH agonists + antiandrogens) and normofractionated RT. ERG expression was evaluated using IHC. Overall survival (OS) was estimated with Kaplan–Meier curves. Prostate cancer-specific survival (PCSS), biochemical recurrence-free survival (bRFS), and progression-free survival (PFS) were assessed using competing risk models.

Results

A total of 86 patients were included (median follow-up 173 months). ERG expression was positive in 69%. No significant differences were observed in OS (HR 1.03; p = 0.92), PCSS (HR 0.44; p = 0.22), bRFS (HR 0.51; p = 0.19), or PFS (HR 0.56; p = 0.30) between ERG-positive and ERG-negative groups.

Conclusions

ERG expression assessed by IHC was not associated with clinical outcomes in this population. These results do not support its role as a predictive biomarker in patients treated with CAB and RT. Further prospective studies are warranted to confirm these findings.